Funded Projects › FP7
TARKINAID · Targeting Src-family tyrosine kinases in chronic autoimmune and inflammatory diseases
The project aims to develop novel inhibitors of chronic autoimmune and inflammatory diseases by targeting members of the Src tyrosine kinase family. Src-family kinases have recently emerged as major therapeutic targets in malignant diseases but their suitability as potential targets of inflammatory diseases has not yet recieved widespread acceptance. On the other hand, members of the applicant consortium have recently obtained genetic evidence showing that myeloid Src-family kinases (Hck, Fgr and Lyn) are indispensable for murine models of autoimmune inflammatory diseases such as rheumatoid arthritis or blistering skin diseases. They also developed a number of novel Src-family kinase inhibitors that also block inflammation-related in vitro leukocyte functions. The applicants will test and further develop novel Src-family kinase inhibitors as anti-inflammatory compounds, using several in vitro and in vivo inflammation assays to optimize the structure of the selected molecules. They will also test whether Src-family inhibitors already in clinical use in oncology patients also inhibit inflammatory processes. Finally, they will use Src-family kinase-deficient mice in several inflammation models to test the role of those kinases in more detail and to provide further reference information for the consortium's preclinical drug development activity. The selected inhibitors and mutant mice will be pre-screened using various inflammation-related in vitro leukocyte functions and short-term in vivo inflammation models, and then analyzed in detail using a number of in vivo mouse models of chronic autoimmune and inflammatory diseases. The project is expected to result in development of novel preclinical drug candidates against chronic autoimmune and inflammatory disease with novel mechanism of action, as well as novel knowledge on the role of Src-family kinases in inflammatory diseases. The project will be performed in close cooperation between European and Brazilian scientists.
Consortium · 11 organisations
SEMMELWEIS EGYETEM
HU · €551,962
UNIVERSITA DEGLI STUDI DI VERONA
IT · €296,082
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
DE · €493,280
UNIVERSIDADE FEDERAL DO RIO DE JANEIRO
BR · €246,822
BIOMEDCODE ELLAS ANONIMI ETERIA EPISTIMONIKIS KAI TEXNOLOGIKIS EREVNAS KAI EMBORIKIS EKMETALLEFSIS EPHARMOGON IATRIKIS
EL · €177,570
VICHEM CHEMIE KUTATO KORLATOLT FELELOSSEGU TARSASAG
HU · €296,010
FUNDACAO OSWALDO CRUZ
BR · €147,978
ALTA RICERCA E SVILUPPO IN BIOTECNOLOGIE SRLU
IT · €100,000
UNIVERSITAETSKLINIKUM FREIBURG
DE · €246,228
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
FR · €295,950
AMBIOTIS
FR · €147,978
Research fields
← Find collaborators and more funded projects
Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.